Puma Biotechnology (NASDAQ:PBYI) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Puma Biotechnology (NASDAQ:PBYI) in a report released on Monday, Benzinga reports. They currently have a $7.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com cut shares of Puma Biotechnology from a buy rating to a hold rating in a research note on Saturday, May 11th.

Puma Biotechnology Price Performance

Shares of Puma Biotechnology stock opened at $4.23 on Monday. The firm has a fifty day simple moving average of $5.04 and a 200-day simple moving average of $4.87. The company has a current ratio of 1.46, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07. Puma Biotechnology has a 1-year low of $2.13 and a 1-year high of $7.73. The stock has a market capitalization of $204.06 million, a price-to-earnings ratio of 12.82, a PEG ratio of 3.15 and a beta of 1.31.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.07). Puma Biotechnology had a return on equity of 35.49% and a net margin of 6.79%. The firm had revenue of $72.20 million during the quarter, compared to analyst estimates of $73.22 million. On average, sell-side analysts expect that Puma Biotechnology will post 0.23 earnings per share for the current year.

Hedge Funds Weigh In On Puma Biotechnology

A number of hedge funds have recently made changes to their positions in PBYI. Jump Financial LLC raised its stake in shares of Puma Biotechnology by 26.6% in the 3rd quarter. Jump Financial LLC now owns 24,690 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 5,190 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of Puma Biotechnology by 143.8% in the 3rd quarter. GSA Capital Partners LLP now owns 279,629 shares of the biopharmaceutical company’s stock valued at $735,000 after buying an additional 164,931 shares in the last quarter. Citigroup Inc. acquired a new position in shares of Puma Biotechnology in the 3rd quarter valued at $262,000. Assenagon Asset Management S.A. raised its stake in shares of Puma Biotechnology by 23.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 85,039 shares of the biopharmaceutical company’s stock valued at $368,000 after buying an additional 15,897 shares in the last quarter. Finally, Ritholtz Wealth Management acquired a new position in shares of Puma Biotechnology in the 4th quarter valued at $66,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.